Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-06-24
- Target Recruit Count
- 376
- Registration Number
- NCT05188313
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Target Recruit Count
- 190
- Registration Number
- NCT05189067
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT05187182
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 185
- Registration Number
- NCT05180006
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Morten Mau-Sørensen
- Target Recruit Count
- 24
- Registration Number
- NCT05170256
- Locations
- 🇩🇰
Dept of Oncology, Rigshospitalet, Copenhagen, Region H, Denmark
🇩🇰Onkologisk Afdeling R, Odense University Hospital, Odense, Region Syd, Denmark
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 918
- Registration Number
- NCT05152147
- Locations
- 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT05132582
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Other, Spain
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 927
- Registration Number
- NCT05113251
- Locations
- 🇹🇭
Research Site, Khon Kaen, Thailand
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT05091528
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.